Spexis AG announced a capital commitment totaling USD $2.5 million with participation from SPRIM Global Investments and institutional investors to fund the upcoming Phase 3 ColiFin® studies, beginning with the COPILOT study which is expected to initiate in the third quarter of 2023.
